

November 23, 2022

→ BSE Limited

Department of Corporate Services, P. J. Towers, Dalal Street

Mumbai - 400 001.

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex, Bandra (East), **Mumbai - 400 051.**

Dear Sir/Madam,

<u>Sub: Disclosure under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements)</u> <u>Regulations, 2015.</u>

In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to enclose disclosure of Related Party Transactions for the half-year ended September 30, 2022.

The above is for your information and dissemination.

Thanking You,

For LUPIN LIMITED

R. V. SATAM COMPANY SECRETARY (ACS - 11973)

Encl: a/a.

PΔN

Details of the party (listed entity /subsidiary)

entering into the transaction

Name

1 Lupin Limited

2 Lupin Limited

3 Lupin Limited

4 Lupin Limited

5 Lupin Limited

6 Lupin Limited

7 Lupin Limited

8 Lupin Limited

9 Lupin Limited

10 Lupin Limited

11 Lupin Limited

12 Lupin Limited

13 Lupin Limited

14 Lupin Limited

15 Lupin Limited

16 Lupin Limited

17 Lupin Limited

18 Lupin Limited

19 Lupin Limited

20 Lupin Limited

21 Lupin Limited

22 Lupin Limited

23 Lupin Limited

24 Lupin Limited

25 Lupin Limited

26 Lupin Limited

27 Lupin Limited

28 Lupin Limited

29 Lupin Limited

30 Lupin Limited

31 Lupin Limited

32 Lupin Limited

33 Lupin Limited

34 Lupin Limited

35 Lupin Limited

36 Lupin Limited

37 Lupin Limited

38 Lupin Limited

39 Lupin Limited

40 Lupin Limited

41 Lupin Limited

42 Lupin Limited

43 Lupin Limited

44 Lupin Limited

45 Lupin Limited

46 Lupin Limited

47 Lupin Limited

48 Lupin Limited

49 Lupin Limited

50 Lupin Limited

51 Lupin Limited

52 Lupin Limited

53 Lupin Limited

Lupin Pharmaceuticals Inc. USA

Lupin Australia Pty Limited, Australia

Hormosan Pharma GmbH, Germany

Multicare Pharmaceuticals Philippines Inc

Lupin Atlantis Holdings SA, Switzerland

Generic Health Pty Limited, Australia

Lupin Pharma Canada Limited Canada

Lupin Diagnostics Limited, India (formerly

uthern Cross Pharma Pty Limited Australia

known as Lupin Healthcare Limited)

Lupin Digital Health Limited, India

Lupin Pharmaceuticals Inc. USA

Hormosan Pharma GmbH, Germany

Multicare Pharmaceuticals Philippines Inc.

Lupin Atlantis Holdings SA, Switzerland

Generic Health Pty Limited, Australia

Lupin Pharma Canada Limited Canada

Lupin Philippines Inc. Philippines

Pharma Dynamics (Proprietary) Limited, South

Medguimica Industria Farmaceutica LTDA Braz

Lupin Healthcare (UK) Limited, UK

Lupin Philippines Inc. Philippines

Nanomi B.V., Netherlands

Lupin Research Inc. USA

Novel Laboratories Inc. USA

Lupin Management Inc., USA

Lupin Oncology Inc., USA

Lupin Inc., USA

Philippines

Lupin Inc., USA

Lupin Research Inc. USA

Zyma Properties Pvt. Limited

Novel Laboratories Inc. USA

upin Pharmaceuticals Inc. USA

Hormosan Pharma GmbH, Germany

upin Healthcare (UK) Limited, UK

Multicare Pharmaceuticals Philippines Inc.

upin Atlantis Holdings SA, Switzerland

Generic Health Pty Limited, Australia

upin Pharma Canada Limited Canada

aboratorios Grin S.A. de C.V., Mexico

Medquimica Industria Farmaceutica LTDA Brazi

upin Philippines Inc. Philippines

Nanomi B.V., Netherlands

upin Research Inc. USA

lovel Laboratories Inc. USA

upin Management Inc., USA

Lupin Diagnostics Limited, India (formerly

(nown as Lupin Healthcare Limited)

upin Digital Health Limited, India

upin Inc., USA

Pharma Dynamics (Proprietary) Limited, South

Lupin Research Inc. USA

Philippines

Africa

Pharma Dynamics (Proprietary) Limited, South

Lupin Healthcare (UK) Limited, UK

Lupin Europe GmbH, Germany

Philippines

Name

Details of Related Parties transactions during the period April 1, 2022 to September 30, 2022

Details of the counterparty

 $P\Delta N$

Relationship of the

counterparty with the listed

entity or its subsidiary

Wholly -Owned Subsidiary

Relative of KMP and Entity in which the KMP and Relatives of KMP have control or

significant influence

Wholly -Owned Subsidiary

ubsidiary

Subsidiary

Subsidiary

Subsidiary

Rs. in Million

Purpose for which the

funds will be utilised by the

ultimate recipient of funds

(endusage)

Details of the loans, inter-corporate deposits, advances or investments

Tenure

nterest

Rate (%)

Secured/

unsecured

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Nature (loan/ advance/

intercorporate deposit/

investment)

Cost | Tenure

In case any financial indebtedness is incurred to

make or give loans, inter-corporate deposits.

advances or investments

indebtedness

debtedness (loan/ Details of other

issuance of debt/

any other etc.)

n case monies are due to

ither party as a result of

Closing

balance

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.0

0.0

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

the transaction

Opening

balance

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

Value of transaction

during the reporting

period

17.79

0.22

2.49

2.45

0.35

1.67

7.16

1.50

2.34

1.82

0.47

1 96

2.12

1.99

3.99

6.2

1.66

0.03

0.18

0.53

9469.79

71.03

445.02

109.13

295.58

670.16

521.08

336.52

46.19

304.06

1685.04

59.30

14.55

323.40

67.66

10.81

6.43

5.06

7.83

4.3

13.75

4.71

2.28

0.00

7.73

9.74

1.90

26.67

10.01

6.70

5.43

23.08

Value of the related party

transaction as approved by

the audit committee

17.79

0.22

2.49

2.45

0.35

1.67

7.16

1.50

2.34

1.82

0.47

1 96

2.12

1.99

3.99

6.2

1.66

0.03

0.18

0.5

9469.79

71.03

445.0

109.13

295.58

670.16

521.08

336.52

46.1

304.06

1685.04

59.30

14.5

323.40

67.66

10.81

6.43

5.06

7.83

4.31

13.75

4.7

2.28

0.00

7.73

9.74

1.90

26.67

10.01

5.4

23.08

2.59

Type of related party transaction

Sale of goods or services

Purchase of goods or services

Purchase of goods or services

Expenses incurred on their behal

Expenses incurred on their behal-

Expenses incurred on their behal

Expenses incurred on their behal

Expenses incurred on their behal-

Expenses incurred on their behal-

Expenses incurred on their behal

Expenses incurred on their behal

Expenses incurred on their behalt

Expenses incurred on their behal-

Expenses incurred on their behal-

Expenses incurred on their behalf

Expenses incurred on their behal

Expenses incurred on their behal-

Expenses incurred on their behalf

Rent Paid

recovered

87 Lupin Limited

88 Lupin Limited

Generic Health Pty Limited, Australia

Lupin Pharma Canada Limited Canada

Rs. in Million

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Details of the party (listed entity /subsidiary) entering into the transaction Sr No.			Details of the coun	iterpa	rty		Value of the related party	Value of transaction	either party	ies are due to as a result of nsaction	In case any financi make or give loa advanc		te dep		Details of the loa	ns, inter-c	orporate	deposits, adv	ances or investments
		PAN	I Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	transaction as approved by the audit committee	during the reporting period	Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
	54 Lupin Limited		Polynova Industries Limited		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Rent received	0.91	0.91	0.00	0.00									
	55 Lupin Limited		Polynova Industries Limited		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Inter-corporate deposit	0.00	0.00	0.10	0.10									
H	33 Eupin Ellinteu		Polynova muustnes tiiniteu	\vdash	significant influence	inter-corporate deposit	0.00	0.00	0.10	0.10									
Ŀ	56 Lupin Limited		Mr. Nilesh D. Gupta	_	Key Management Personnel	Remuneration	26.53	26.53	0.00	0.00									
	57 Lupin Management Inc., USA		Ms. Vinita Gupta		Key Management Personnel	Remuneration	52.66	52.66	0.00	0.00									
	58 Lupin Limited		Mr. Ramesh Swaminathan		Key Management Personnel	Remuneration	34.02	34.02	0.00	0.00									
Ш.	501 - 2-12-2-1		Mr. R. V. Satam		W. M	B			0.00	0.00									
	59 Lupin Limited 60 Lupin Limited		Dr. Kamal K. Sharma	1	Key Management Personnel Non- Executive Director	Remuneration Sitting Fees	5.29 0.16		0.00										
	61 Lupin Limited		Mr. Jean-Luc Belingard	<u> </u>	Independent Director	Sitting Fees	0.02		0.00										
	62 Lupin Limited		Ms. Christine Ann Mundkur	 	Independent Director	Sitting Fees	0.14		0.00										
	63 Lupin Limited		Mr. K.B.S. Anand		Independent Director	Sitting Fees	0.08		0.00										
	64 Lupin Limited		Dr. Punita Kumar-Sinha		Independent Director	Sitting Fees	0.12		0.00										
	65 Lupin Limited		Mrs. Manju D. Gupta		Non- Executive Director	Sitting Fees	0.08	0.08	0.00	0.00									
	66 Lupin Limited		Mr. Mark D. Mcdade		Independent Director	Sitting Fees	0.06	0.06	0.00										
- (67 Lupin Limited		Lupin Research Inc. USA		Wholly -Owned Subsidiary	Purchase of goods or services	168.76	168.76	0.00	0.00									
	68 Lupin Limited		Shuban Prints		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Purchase of goods or services	33.15	33.15	0.00										
-	69 Lupin Limited		S. N. Pharma		Relative of KMP and Entity in	Purchase of goods or services	40.50												
	70 Lupin Limited		Lupin Biologics Limited, India		Wholly -Owned Subsidiary	Investment	0.50		1.00										
	71 Lupin Limited		Lupin Digital Health Limited, India		Wholly -Owned Subsidiary	Investment	297.00	297.00	400.10	697.10									
	72 Lupin Limited		Lupin Human Welfare and Research Foundation		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Donation	8.79	8.79	0.00	0.00									
					Relative of KMP and Entity in which the KMP and Relatives														

57	Lupin Management Inc., USA	Ms. Vinita Gupta	Key Management Personnel	Remuneration	52.66	52.66	0.00	0.00						
58	Lupin Limited	Mr. Ramesh Swaminathan	Key Management Personnel	Remuneration	34.02	34.02	0.00	0.00						
59	Lupin Limited	Mr. R. V. Satam	Key Management Personnel	Remuneration	5.29	5.29	0.00	0.00						
	Lupin Limited	Dr. Kamal K. Sharma	Non- Executive Director	Sitting Fees	0.16	0.16	0.00	0.00						
	Lupin Limited	Mr. Jean-Luc Belingard	Independent Director	Sitting Fees	0.02	0.02	0.00							
	Lupin Limited	Ms. Christine Ann Mundkur	Independent Director	Sitting Fees	0.14	0.14	0.00					1 1		
	Lupin Limited	Mr. K.B.S. Anand	Independent Director	Sitting Fees	0.08	0.08	0.00					_		
	Lupin Limited	Dr. Punita Kumar-Sinha	Independent Director	Sitting Fees	0.12	0.12	0.00					1	_	
	Lupin Limited	Mrs. Manju D. Gupta	Non- Executive Director	Sitting Fees	0.12	0.08	0.00							
		Mr. Mark D. Mcdade	Independent Director	Sitting Fees Sitting Fees	0.08	0.08	0.00			_			_	
	Lupin Limited									_			_	
67	Lupin Limited	Lupin Research Inc. USA	Wholly -Owned Subsidiary	Purchase of goods or services	168.76	168.76	0.00	0.00				++	_	
			Relative of KMP and Entity in											
			which the KMP and Relatives											
			of KMP have control or											
	Lupin Limited	Shuban Prints	significant influence	Purchase of goods or services	33.15	33.15	0.00							
69	Lupin Limited	S. N. Pharma	Relative of KMP and Entity in	Purchase of goods or services	40.50	40.50	0.00	0.00						
	Lupin Limited	Lupin Biologics Limited, India	Wholly -Owned Subsidiary	Investment	0.50	0.50	1.00	1.50						
71	Lupin Limited	Lupin Digital Health Limited, India	Wholly -Owned Subsidiary	Investment	297.00	297.00	400.10	697.10						
			Relative of KMP and Entity in											
			which the KMP and Relatives											
			of KMP have control or											
		l												
/2	Lupin Limited	Lupin Human Welfare and Research Foundation	significant influence	Donation	8.79	8.79	0.00	0.00						
			Relative of KMP and Entity in											
			which the KMP and Relatives											
			of KMP have control or											
	Lupin Limited	Mata Shree Gomati Devi Jan Seva Nidhi	significant influence	Donation	5.40	5.40	0.00	0.00						
	Lupin Limited	Lupin Pharmaceuticals Inc. USA	Wholly -Owned Subsidiary	Purchase of goods or services	36.19	36.19	0.00	0.00						
75	Lupin Limited	Hormosan Pharma GmbH, Germany	Wholly -Owned Subsidiary	Purchase of goods or services	10.48	10.48	0.00	0.00						
76	Lupin Limited	Lupin Healthcare (UK) Limited, UK	Wholly -Owned Subsidiary	Purchase of goods or services	75.79	75.79	0.00	0.00						
	Lupin Limited	Lupin Atlantis Holdings SA, Switzerland	Wholly -Owned Subsidiary	Purchase of goods or services	28.99	28.99	0.00							
	Lupin Limited	Lupin Inc., USA	Wholly -Owned Subsidiary	Purchase of goods or services	74.99	74.99	0.00							
	Lupin Limited	Lupin Management Inc., USA	Wholly -Owned Subsidiary	Purchase of goods or services	201.07	201.07	0.00						_	
/5	Eupin Einnteu	Eupin Management IIIc., OSA	Wildily -Owned Subsidiary	Fulctiase of goods of services	201.07	201.07	0.00	0.00		_			_	
			Butter a fire and a state of the											
			Relative of KMP and Entity in											
			which the KMP and Relatives											
			of KMP have control or											
80	Lupin Limited	Team Lease Services Limited	significant influence	Purchase of goods or services	21.79	21.79	0.00	0.00						
			Relative of KMP and Entity in											
			which the KMP and Relatives											
			of KMP have control or		1									
81	Lupin Limited	S. N. Pharma	significant influence	Purchase of goods or services	13.39	13.39	0.00	0.00				1 1		
-	.,			Expenses incurred on our behalf	13.33	25.55	5.00							
			1	reimbursed & Other	1									
,,	Lupin Limited	Lupin Pharmaceuticals Inc. USA	Wholly -Owned Subsidiary	Reimbursements	240.49	240.49	0.00	0.00						
82	Lupin Linned	Eupin Friai Maceuticais Inc. USA	viriolly -Owned Subsidiary		240.49	240.49	0.00	0.00		_		+ +	-	
			1	Expenses incurred on our behalf								1 1		
			1	reimbursed & Other	1									
83	Lupin Limited	Lupin Australia Pty Limited, Australia	Wholly -Owned Subsidiary	Reimbursements	29.94	29.94	0.00	0.00				\perp		
			1	Expenses incurred on our behalf	1									
		1		reimbursed & Other	1			1		1	1	1		

			which the KIVIP and Relatives										
			of KMP have control or										
1	3 Lupin Limited	Mata Shree Gomati Devi Jan Seva Nidhi	significant influence	Donation	5.40	5.40	0.00	0.00					
	4 Lupin Limited	Lupin Pharmaceuticals Inc. USA	Wholly -Owned Subsidiary	Purchase of goods or services	36.19	36.19	0.00	0.00					
	5 Lupin Limited	Hormosan Pharma GmbH, Germany	Wholly -Owned Subsidiary	Purchase of goods or services	10.48	10.48	0.00	0.00					
Z	6 Lupin Limited	Lupin Healthcare (UK) Limited, UK	Wholly -Owned Subsidiary	Purchase of goods or services	75.79	75.79	0.00	0.00					
Z	7 Lupin Limited	Lupin Atlantis Holdings SA, Switzerland	Wholly -Owned Subsidiary	Purchase of goods or services	28.99	28.99	0.00	0.00					
7	8 Lupin Limited	Lupin Inc., USA	Wholly -Owned Subsidiary	Purchase of goods or services	74.99	74.99	0.00	0.00					
	9 Lupin Limited	Lupin Management Inc., USA	Wholly -Owned Subsidiary	Purchase of goods or services	201.07	201.07	0.00	0.00					
	0 Lupin Limited	Team Lease Services Limited	Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Purchase of goods or services	21.79	21.79	0.00	0.00					
8	1 Lupin Limited	S. N. Pharma	Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Purchase of goods or services	13.39	13.39	0.00	0.00					
8	2 Lupin Limited	Lupin Pharmaceuticals Inc. USA	Wholly -Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	240.49	240.49	0.00	0.00					
	3 Lupin Limited	Lupin Australia Pty Limited, Australia	Wholly -Owned Subsidiary	Expenses incurred on our behalf reimbursed & Other Reimbursements	29.94	29.94	0.00	0.00					
				Expenses incurred on our behalf reimbursed & Other									

79 Lupin Limited	Lupin Management Inc., USA	Wholly -Owned Subsidiary	Purchase of goods or services	201.07	201.07	0.00	0.00						
		Relative of KMP and Entity in											
		which the KMP and Relatives											
		of KMP have control or											
80 Lupin Limited	Team Lease Services Limited	significant influence	Purchase of goods or services	21.79	21.79	0.00	0.00						
oo Eupin Eiiniteu	Team Leade Services Limited	Significant influence	Turenase or goods or services	22.73	22.75	0.00	0.00				-		
		Relative of KMP and Entity in											
		which the KMP and Relatives											
		of KMP have control or											
l ad le construire	S. N. Pharma	significant influence	B	13.39	13.39	0.00	0.00						
81 Lupin Limited	S. N. Pharma	significant influence	Purchase of goods or services	13.39	13.39	0.00	0.00						
			Expenses incurred on our behalf										
			reimbursed & Other	l									
82 Lupin Limited	Lupin Pharmaceuticals Inc. USA	Wholly -Owned Subsidiary	Reimbursements	240.49	240.49	0.00	0.00		-				
			Expenses incurred on our behalf										
			reimbursed & Other										
83 Lupin Limited	Lupin Australia Pty Limited, Australia	Wholly -Owned Subsidiary	Reimbursements	29.94	29.94	0.00	0.00				—		
			Expenses incurred on our behalf										
			reimbursed & Other										
84 Lupin Limited	Hormosan Pharma GmbH, Germany	Wholly -Owned Subsidiary	Reimbursements	7.94	7.94	0.00	0.00						
			Expenses incurred on our behalf										
			reimbursed & Other										
85 Lupin Limited	Lupin Europe GmbH, Germany	Wholly -Owned Subsidiary	Reimbursements	2.31	2.31	0.00	0.00						
			Expenses incurred on our behalf										
	Pharma Dynamics (Proprietary) Limited, South		reimbursed & Other									1	
86 Lupin Limited	Africa	Wholly -Owned Subsidiary	Reimbursements	3.25	3.25	0.00	0.00		1			1	
		1	Expenses incurred on our hehalf							1			

26.36

26.36

0.00

0.00

reimbursed & Other

Reimbursements Expenses incurred on our behalf reimbursed & Other

Reimbursements

Wholly -Owned Subsidiary

Wholly -Owned Subsidiary

0.00

0.00

0.00

0.00

0.00

0.00

21.60

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

3.39

35.86

33.19

20.22

0.00

0.00

0.00

0.00

21.60

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

35.86

3.39

33.19

6.99

20.22

0.00

13.79

33 32

32805.56

50885.21

1127.85

0.00

717 09

31.95

47 93

2.57

40.70

0.61

30.07

14.04

291.42

8.97

0.00

96.45

0.00

0.02

1.32

35.47

0.00

0.00

0.00

0.00

0.00

13.79

33.3

32805.56

50885.23

1081.6

1127.85

0.00

162 84

18.47

95.91

2.31

3.31

3.58

14.79

48.77

15.07

766.19

102.27

178.30

0.40

1.23

0.90

0.02

2.5

50.98

0.00

0.00

0.00

0.00

0.00

8.31

95 Lupin Limited

96 Lupin Limited

97 Lupin Limited

98 Lupin Limited

99 Lupin Limited

100 Lupin Limited

101 Lupin Limited

102 Lupin Limited

103 Lupin Limited

104 Lupin Limited

105 Lupin Limited

106 Lupin Limited

107 Lupin Limited

108 Lupin Limited

109 Lupin Limited

110 Lupin Limited

111 Lupin Limited

112 Lupin Limited

113 Lupin Limited

114 Lupin Limited

115 Lupin Limited

116 Lupin Limited

117 Lupin Limited

118 Lupin Limited

119 Lupin Limited

120 Lupin Limited

121 Lupin Limited

122 Lupin Limited

123 Lupin Limited

124 Lupin Limited

125 Lupin Limited

126 Lupin Limited

Lupin Pharmaceuticals Inc. USA

Nanomi B.V., Netherlands

Lupin Oncology Inc., USA

Zyma Properties Pvt. Limited

Zyma Properties Pvt. Limited

Lupin Pharmaceuticals Inc. USA

Hormosan Pharma GmbH, Germany

Lupin Atlantis Holdings SA, Switzerland

Generic Health Ptv Limited, Australia

Lupin Research Inc. USA

Novel Laboratories Inc. USA

Lupin Management Inc., USA

Team Lease Services Limited

Lupin Australia Pty Limited, Australia

Novel Laboratories Inc. USA

Nanomi B.V., Netherlands

upin Pharmaceuticals Inc. USA

Medquimica Industria Farmaceutica LTDA Brazil

Shuban Prints

S. N. Pharma

Lupin Inc., USA

Dr. Kamal K. Sharma

Lupin Digital Health Limited, India

Lupin Pharma Canada Limited Canada

Pharma Dynamics (Proprietary) Limited, South

Medquimica Industria Farmaceutica LTDA Brazi

Lupin Diagnostics Limited, India (formerly

known as Lupin Healthcare Limited)

Lupin Healthcare (UK) Limited, UK

Lupin Europe GmbH, Germany

Lupin Australia Pty Limited, Australia

known as Lupin Healthcare Limited)

Lupin Atlantis Holdings SA, Switzerland

Lupin Diagnostics Limited, India (formerly

Wholly -Owned Subsidiary

Relative of KMP and Entity in which the KMP and Relatives of KMP have control or

Relative of KMP and Entity in which the KMP and Relatives of KMP have control or

significant influence

significant influence

Wholly -Owned Subsidiary

Relative of KMP and Entity in which the KMP and Relatives of KMP have control or

Relative of KMP and Entity in which the KMP and Relatives of KMP have control or

Relative of KMP and Entity in which the KMP and Relatives of KMP have control or

significant influence

significant influence

significant influence

Wholly -Owned Subsidiary

Non- Executive Director

Wholly -Owned Subsidiary

Subsidiary

Investment

Investment

Investment

Investment

Investment

Inter-corporate deposit

Inter-corporate deposit

Payables

Payables

Payables

Payables

Payables

Payables

Pavables

Payables

Pavables

Payables

Payables

Payables

Pavables

Pavables

Payables

Payables

Pavables

Payables

Pavables

Sale of fixed assets

Sale of fixed assets

ees received against guarantee

Fees received against guarantee

Fees received against guarantee

provided on their behalf

provided on their behalf

provided on their behalf

Rs. in Million

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the

														rep	orting p	eriod when such transaction	n was un	dertaken.		, ,
	Details of the party (listed entity /subsidia entering into the transaction	ary)	Details of the count	terpa	arty		Value of the related party	Value of transaction			s are due to s a result of saction	In case any financia make or give loan advance		s incur e depo	red to					nces or investments
Sr No.	Name	PAN		PAI	entity or its subsidiary	Type of related party transaction	transaction as approved by the audit committee	during the reporting period	b	pening palance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
	Lupin Limited		Lupin Atlantis Holdings SA, Switzerland		Wholly -Owned Subsidiary	Sale of goods or services	72.47			0.00	0.00									
	Lupin Limited		Lupin Inc., USA	┝	Wholly -Owned Subsidiary	Sale of goods or services	8.52			0.00	0.00									
	Lupin Limited Lupin Limited	-	Lupin Research Inc. USA		Wholly -Owned Subsidiary Subsidiary	Sale of goods or services	0.17 908.89			0.00	0.00			\vdash						
	Lupin Limited	-	Lupin Oncology Inc., USA Novel Laboratories Inc. USA	\vdash	Wholly -Owned Subsidiary	Sale of goods or services Purchase of fixed assets	49.55		-	0.00	0.00			\vdash						
131	Eupin Emitted		Lupin Diagnostics Limited, India (formerly	H	Wildily -Owned Subsidiary	Fulctiase of fixed assets	45.53	45.3.	1	0.00	0.00									
132	Lupin Limited		known as Lupin Healthcare Limited)		Wholly -Owned Subsidiary	Purchase of fixed assets	0.04	0.04	1	0.00	0.00									
	Lupin Limited		Dr. Kamal K. Sharma		Non- Executive Director	Settlement of liabilities by entity on behalf of related party Letter of Comfort issued by the	3.37	3.37	7	0.00	0.00									
	'					Company to the bankers of														
134	Lupin Limited		Lupin Pharmaceuticals Inc. USA		Wholly -Owned Subsidiary	subsidiary companies	1974.31		1	0.00	0.00									
135	Lupin Limited		Lupin Philippines Inc. Philippines		Wholly -Owned Subsidiary	Payables	0.00			0.05	0.00									
	Lupin Limited		Generic Health Pty Limited, Australia	-	Wholly -Owned Subsidiary	Receivables	0.00			264.41	283.37									
	Lupin Limited		Hormosan Pharma GmbH, Germany	\vdash	Wholly -Owned Subsidiary	Receivables	0.00			10.60	4.13									
	Lupin Limited Lupin Limited		Laboratorios Grin S.A. de C.V., Mexico Lupin Europe GmbH, Germany	\vdash	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Receivables Receivables	0.00			2.68 0.16	1.27 0.18			\vdash				-	\vdash	
	Lupin Limited Lupin Limited		Lupin Europe GmbH, Germany Lupin Atlantis Holdings SA, Switzerland	\vdash	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Receivables	0.00			245.52	413.10			\vdash						
	Lupin Limited		Lupin Australia Pty Limited, Australia		Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Receivables	0.00			0.00	0.10			\vdash						
	Lupin Limited		Lupin Biologics Limited, India	т	Wholly -Owned Subsidiary	Receivables	0.00			0.00	0.00			\vdash						
	Lupin Limited		Lupin Digital Health Limited, India		Wholly -Owned Subsidiary	Receivables	0.00			1.34	2.86			П						
	Lupin Limited		Lupin Healthcare (UK) Limited, UK		Wholly -Owned Subsidiary	Receivables	0.00			356.28	664.12									
	l		Lupin Diagnostics Limited, India (formerly											ΙĪ					7	7.1
	Lupin Limited	1	known as Lupin Healthcare Limited)	\vdash	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Receivables	0.00			5.07 7.84	4.50 24.44			\vdash						
	Lupin Limited Lupin Limited	1	Nanomi B.V., Netherlands Lupin Inc., USA	\vdash	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Receivables Receivables	0.00			6842.46	1763.45			\vdash						
	Lupin Limited		Lupin Management Inc., USA		Wholly -Owned Subsidiary	Receivables	0.00			3.10	7.37			\vdash						
	Lupin Limited		Lupin Oncology Inc., USA		Subsidiary	Receivables	0.00			812.57	1794.71									
	Lupin Limited		Lupin Pharma Canada Limited Canada		Wholly -Owned Subsidiary	Receivables	0.00			248.36	333.27									
	Lupin Limited		Lupin Pharmaceuticals Inc. USA		Wholly -Owned Subsidiary	Receivables	0.00			12801.67	13621.33									
	Lupin Limited		Lupin Philippines Inc. Philippines	L	Wholly -Owned Subsidiary	Receivables	0.00			270.73	238.18									
153	Lupin Limited		Lupin Research Inc. USA		Wholly -Owned Subsidiary	Receivables	0.00	0.00		30.92	53.84									
154	Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil		Wholly -Owned Subsidiary	Receivables	0.00	0.00		374.35	275.73									
			Multicare Pharmaceuticals Philippines Inc.																	
	Lupin Limited Lupin Limited	-	Philippines Nevel Laboratories Inc. USA	-	Subsidiary Wholly -Owned Subsidiary	Receivables	0.00			52.52 5.82	75.54 39.15			$\vdash\vdash$						
156	Eupin Ellinteu	1	Novel Laboratories Inc. USA Pharma Dynamics (Proprietary) Limited, South		writing -Owned Subsidiary	Receivables	0.00	0.00	1	5.82	39.15			\vdash						
157	Lupin Limited		Africa	L	Wholly -Owned Subsidiary	Receivables	0.00	0.00	0	173.72	179.03							<u></u>		
158	Lupin Limited		Southern Cross Pharma Pty Limited Australia		Wholly -Owned Subsidiary	Receivables	0.00	0.00		0.00	0.35									
	Lupin Limited		Generic Health Pty Limited, Australia		Wholly -Owned Subsidiary	Corporate guarantees issued by the Company to the bankers of subsidiary company	0.00			0.00	1320.44									
160	Lupin Limited		Lupin Healthcare (UK) Limited, UK		Wholly -Owned Subsidiary	Corporate guarantees issued by the Company to the bankers of subsidiary company	0.00	0.00	o	64.65	59.02									
1 1														ıΙ						7.
161	Lupin Limited		Lupin Pharmaceuticals Inc. USA		Wholly -Owned Subsidiary	Corporate guarantees issued by the Company to the bankers of subsidiary company	0.00	0.00) 2	28895.89	35080.03									
162	Lupin Limited		Medquimica Industria Farmaceutica LTDA Brazil		Wholly -Owned Subsidiary	Corporate guarantees issued by the Company to the bankers of subsidiary company	0.00	0.00		5840.19	2056.50									
163	Lupin Limited		Nanomi B.V., Netherlands		Wholly -Owned Subsidiary	Guarantees issued by the Company on behalf of subsidiary company for contractual obligations	0.00	0.00		5075.07	5446.86									
					F-17 h- 1 12					T]					7	7.
164	Lupin Limited		Lupin Investments Pvt. Limited			Dividend paid	828.78	828.78	3	0.00	0.00									
165	Lupin Limited		Dr. Anuja Gupta (Daughter of Chairman)		Relative of KMP and Entity in which the KMP and Relatives of KMP have control or significant influence	Dividend paid	2.90	2.90		0.00	0.00									
					Relative of KMP and Entity in which the KMP and Relatives of KMP have control or															
166	Lupin Limited		Ms. Kavita Gupta (Daughter of Chairman)		significant influence	Dividend paid	0.80	0.80		0.00	0.00									
					Relative of KMP and Entity in which the KMP and Relatives of KMP have control or															
167	Lupin Limited		Dr. Richa Gupta (Daughter of Chairman)	_	significant influence	Dividend paid	0.93	0.93	3	0.00	0.00			Ш						

Deta	ils of Related Parties transactions during the peri	iod April 1, 2022 to September 30, 2022																Rs. in Million
	G																	es to loans, inter-corporate
										deposits, advance	s or investments r			y the listed entity/subsidia eriod when such transaction				losed only once, during the
							1							erioù wrieri sucii transactio	JII was uii	uertakeri.	•	
	Details of the party (listed entity /subsidiary)	Details of the count	orna	rtu					nies are due to y as a result of					Dotails of the lear	ar inter c	ornorato d	donorite adu	ances or investments
	entering into the transaction	Details of the count	егра	rty					y as a result of ansaction		ans, inter-corporat ces or investment		SILS,	Details of the loar	is, inter-ci	orporate (ueposits, auv	ances or investments
Sr	I	+		T	T of coloted and the constitut	Value of the related party	Value of transaction				1						1	
No.				Relationship of the	Type of related party transaction	transaction as approved by the audit committee	during the reporting period			Nature of				Nature (loan/ advance/				Purpose for which the
	Name PAI	N Name	PAN					Opening	Closing	indebtedness (loan/		Cost	Tenure	intercorporate deposit/	Interest	Tenure	Secured/	funds will be utilised by the
				entity or its subsidiary				balance	balance	issuance of debt/	indebtedness			investment)	Rate (%)		unsecured	ultimate recipient of funds (endusage)
ш										any other etc.)								(endusage)
				Relative of KMP and Entity in														
				which the KMP and Relatives														
		Ms. Shefali Nath Gupta (Wife of Managing		of KMP have control or														
168	Lupin Limited	Director)		significant influence	Dividend paid	0.01	0.01	0.0	0.00	o l								
				Relative of KMP and Entity in														
		Miss Veda Nilesh Gupta (Daughter of Managing		which the KMP and Relatives of KMP have control or														
169	Lupin Limited	Director)		significant influence	Dividend paid	0.28	0.28	0.0	0.00									
				Relative of KMP and Entity in														
		Marter Neel Deckhandhii Ciinte /Son of		which the KMP and Relatives of KMP have control or					1									
170	Lupin Limited	Master Neel Deshbandhu Gupta (Son of Managing Director)		of KMP have control or significant influence	Dividend paid	0.10	0.10	0.0	0.00									
1/5				B-meant imacrice		0.10	3.10	3.0	0.00			\vdash						
				Relative of KMP and Entity in					1									
				which the KMP and Relatives														
,_,	Lupin Limited	D. B. Gupta (HUF)		of KMP have control or	Dividend no:													
	Lupin Limited Lupin Limited	D. B. Gupta (HUF) Mrs. Manju D. Gupta		significant influence Non- Executive Director	Dividend paid Dividend paid	2.59		0.0				\vdash				—		
1					para	15.40	25.40	3.0	5.00			\Box						
				Relative of KMP and Entity in														
				which the KMP and Relatives														
172	Lupin Limited	Mrs. Manju D. Gupta (as Trustee of Gupta Family Trust)		of KMP have control or significant influence	Dividend paid	0.00	0.00	0.0	0.00									
	Lupin Limited Lupin Limited	Dr. Kamal K. Sharma		Non- Executive Director	Dividend paid Dividend paid	0.00						\vdash						
						0.50	0.50	0.0	5.00	1		\Box						
175	Lupin Limited	Ms. Vinita Gupta		Key Management Personnel	Dividend paid	1.31	1.31	0.0	0.00	D		\sqcup						
		has artists a control			Dr. Marchaeld													
176	Lupin Limited	Mr. Nilesh D. Gupta		Key Management Personnel	Dividend paid	3.60	3.60	0.0	0.00	1		\vdash						
177	Lupin Limited	Mr. Ramesh Swaminathan		Key Management Personnel	Dividend paid	0.01	0.01	0.0	0.00	D		L l						
	Lupin Limited	Dr. Punita Kumar-Sinha		Independent Director	Dividend paid	0.00												
	Ii. Limited	Ma B V Catara		Kan Managan	Dividend anid		0.02											
	Lupin Limited Multicare Pharmaceuticals Philippines Inc.	Mr. R. V. Satam		Key Management Personnel	Dividend paid	0.02	0.02	0.0	0.00)		\vdash						
	Philippines	Lupin Philippines Inc. Philippines		Fellow Subsidiary	Sale of goods or services		0.17	0.0	0.00									
	Multicare Pharmaceuticals Philippines Inc.																	
	Philippines	Lupin Philippines Inc. Philippines		Fellow Subsidiary	Purchase of goods or services		103.70	0.0	0.00									
	Multicare Pharmaceuticals Philippines Inc. Philippines	Lupin Philippines Inc. Philippines		Fellow Subsidiary	Payables		0.00	255.1	.6 288.50									
	Multicare Pharmaceuticals Philippines Inc.						5.03											
	Philippines	Lupin Philippines Inc. Philippines		Fellow Subsidiary	Receivables		0.00	0.0										
184	Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Purchase of goods or services		0.25	0.0	0.00	9	-	\vdash						
					Expenses incurred on our behalf reimbursed & Other													
185	Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Reimbursements		1.96	0.0	0.00									
186	Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Loan		14.06	2.8	4 16.90)								
	Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Receivables		0.00					ш						
188	Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia		Fellow Subsidiary	Payables		0.00	0.1	.4 0.29	9	-	\vdash				-	-	
189	Generic Health Ptv Limited. Australia	Southern Cross Pharma Ptv Limited Australia		Fellow Subsidiary	Investment		0.00	1665.9	5 1665.95	<u>.</u>								
	,,	,		,								\Box						
190	Generic Health Pty Limited, Australia	Southern Cross Pharma Pty Limited Australia		Fellow Subsidiary	Loan		46.36	17.0	2 63.38	3	1	$\vdash \vdash$						
101	Generic Health Pty Limited, Australia	Southern Cross Pharma Pty Limited Australia		Fellow Subsidiary	Payables		0.00	0.0	0 14.47	,								
131	25 readarrey Ellinteu, Adstralia	222 and in Gross i manna i ty Emilieu Australia		. Show Substituting	,		0.00	0.0	14.47	1		\vdash						
192	Lupin Atlantis Holdings SA, Switzerland	Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Receivables		0.00	38.2	6 64.97	7		Ш						
	I a sub-unitaria de la compania del compania del compania de la compania del compania de la compania del compania de la compania del c			Sally Charles	Description													
193	Lupin Atlantis Holdings SA, Switzerland	Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Receivables		0.00	110.7	2 63.88	5	1	\vdash					-	
194	Lupin Atlantis Holdings SA, Switzerland	Nanomi B.V., Netherlands		Fellow Subsidiary	Receivables		0.00	1.7	6 1.55	5		L l					<u></u>	
		·																
195	Lupin Atlantis Holdings SA, Switzerland	Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Receivables		0.00	1057.0	7 1219.53	3		$\vdash \vdash$				-		
196	Lupin Atlantis Holdings SA, Switzerland	Pharma Dynamics (Proprietary) Limited, South Africa		Fellow Subsidiary	Receivables		0.00	1.6	6 1.54	1								
123	, and the same of						5.00	2.0	1.5			\vdash						
197	Lupin Atlantis Holdings SA, Switzerland	Lupin Inc., USA		Fellow Subsidiary	Receivables		0.00	1.5	8 0.00	p		\sqcup						
100	Lupin Atlantis Holdings SA, Switzerland	Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Pavables		0.00	12.7		,								
198	Lupin Atlantis noitings 5A, SWITZERIAND	normosan Pharma GmbH, Germany		renow subsidiary	Payables		0.00	12./	3 62.01	+	1	\vdash					-	
199	Lupin Atlantis Holdings SA, Switzerland	Lupin Europe GmbH, Germany		Fellow Subsidiary	Payables		0.00	19.5	3 4.99	9								
200	Lupin Atlantis Holdings SA, Switzerland	Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Payables		0.00	5.2	5 13.08	3	-	\vdash						
201	Lupin Atlantis Holdings SA, Switzerland	Lupin Inc., USA		Fellow Subsidiary	Payables		0.00	6.5	0 3.78	3								
												\Box						
202	Lupin Atlantis Holdings SA, Switzerland	Lupin Management Inc., USA		Fellow Subsidiary	Payables		0.00	19.0	0 15.22	2	1	\square					1	
202	Lupin Atlantis Holdings SA, Switzerland	Lupin Pharma Canada Limited Canada		Fellow Subsidiary	Payables		0.00	88.1	.0 193.57	,								
203	zapin Adamas Holumgs SA, SWIZEHallu	Espiri narma Canada Ellilleu Canada		I CHOM Subsidially	j. dyddies	1	0.00	00.1	155.57	'1	1							

upin Research Inc. USA

Nanomi B.V., Netherlands

upin Europe GmbH, Germany

upin Inc., USA

upin Inc., USA

upin Healthcare (UK) Limited, UK

upin Pharma Canada Limited Canada

aboratorios Grin S.A. de C.V., Mexico

upin Healthcare (UK) Limited, UK

Nanomi B.V., Netherlands

Medguimica Industria Farmaceutica LTDA Brazi

Medquimica Industria Farmaceutica LTDA Brazi

Medquimica Industria Farmaceutica LTDA Brazil

Hormosan Pharma GmbH. Germany

upin Pharma Canada Limited Canada

upin Pharmaceuticals Inc. USA

upin Management Inc., USA

upin Pharmaceuticals Inc. USA

Hormosan Pharma GmbH, Germany

Lupin Healthcare (UK) Limited, UK

Hormosan Pharma GmbH, Germany

upin Healthcare (UK) Limited, UK

upin Pharmaceuticals Inc. USA

upin Europe GmbH, Germany

Hormosan Pharma GmbH. Germany

upin Research Inc. USA

Lupin Inc., USA

upin Pharma Canada Limited Canada

Pharma Dynamics (Proprietary) Limited, South

Nanomi B.V., Netherlands

Africa

upin Inc., USA

aboratorios Grin S.A. de C.V., Mexico

upin Healthcare (UK) Limited, UK

Nanomi B.V., Netherlands

upin Inc., USA

upin Inc., USA

aboratorios Grin S.A. de C.V., Mexico

Fellow Subsidiary

Payables

Payables

Investment

Investment

Investment

Investment

Investment

Investment

Loan

Loan

Loan

Interest received

Interest received

Interest received

nterest received

Dividend received

Interest received

Sale of goods or services

Sale of goods or services

Sale of goods or services

Purchase of goods or services

Reimbursements

Reimbursements

Reimbursements

Expenses incurred on our behalf reimbursed & Other

Expenses incurred on our behalf reimbursed & Other

Expenses incurred on our behalf reimbursed & Other

Other Income

Other Income

Other Income

Other Income

Other Income

entering into the transaction

205 Lupin Atlantis Holdings SA, Switzerland

206 Lupin Atlantis Holdings SA, Switzerland

207 Lupin Atlantis Holdings SA, Switzerland

208 Lupin Atlantis Holdings SA, Switzerland

209 Lupin Atlantis Holdings SA, Switzerland

210 Lupin Atlantis Holdings SA, Switzerland

211 Lupin Atlantis Holdings SA, Switzerland

212 Lupin Atlantis Holdings SA, Switzerland

213 Lupin Atlantis Holdings SA, Switzerland

214 Lupin Atlantis Holdings SA, Switzerland

215 Lupin Atlantis Holdings SA, Switzerland

216 Lupin Atlantis Holdings SA, Switzerland

217 Lupin Atlantis Holdings SA, Switzerland

218 Lupin Atlantis Holdings SA, Switzerland

219 Lupin Atlantis Holdings SA, Switzerland

220 Lupin Atlantis Holdings SA, Switzerland

221 Lupin Atlantis Holdings SA, Switzerland

222 Lupin Atlantis Holdings SA, Switzerland

223 Lupin Atlantis Holdings SA, Switzerland

224 Lupin Atlantis Holdings SA, Switzerland

225 Lupin Atlantis Holdings SA, Switzerland

226 Lupin Atlantis Holdings SA, Switzerland

227 Lupin Atlantis Holdings SA, Switzerland

228 Lupin Atlantis Holdings SA, Switzerland

229 Lupin Atlantis Holdings SA, Switzerland

230 Lupin Atlantis Holdings SA, Switzerland

231 Lupin Atlantis Holdings SA, Switzerland

232 Lupin Atlantis Holdings SA, Switzerland

233 Lupin Atlantis Holdings SA, Switzerland

234 Lupin Atlantis Holdings SA, Switzerland

235 Lupin Atlantis Holdings SA, Switzerland

236 Lupin Atlantis Holdings SA, Switzerland

237 Lupin Atlantis Holdings SA, Switzerland

238 Lupin Atlantis Holdings SA, Switzerland

239 Lupin Atlantis Holdings SA, Switzerland

240 Lupin Atlantis Holdings SA, Switzerland

241 Lupin Atlantis Holdings SA, Switzerland

242 Lupin Atlantis Holdings SA, Switzerland

5.32% 9 yrs

1.25% 2 yrs

1.75% 3 vrs

2.00% 3 yrs

2.25% 3 yrs

loan

Unsecured Business Purpose

Unsecured Business Purpose

Unsecured Business Purpose

Jnsecured Business Purpose

Business Purpose

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate

Rs in Million

reporting period when such transaction was undertaken. In case monies are due to In case any financial indebtedness is incurred to Details of the party (listed entity /subsidiary) Details of the counterparty either party as a result of make or give loans, inter-corporate deposits, Details of the loans, inter-corporate deposits, advances or investments

0.00

0.00

0.00 0.00

0.00

0.00

0.00

1554 56

126.04

69.26

640.67

166 56

572.69

10.54

4.80

23.91

246.92

5.56

436.35

743.21

0.00

7.68

29.28

0.82

15.26

4.57

1.49

3.03

0.00

122.20

25.53

184.52

0.81

13.77

8.18

0.12

0.00

14.91

0.00

6149.55

40 95

279.75

250.76

4170.25

21222 04

439.87

795.64

341.47

2273 79

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

1.87

6149.55

40 95

279.7

250.7

4170.25

22776 60

313.83

726.38

982.15

2440 35

572 69

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

						Value of the related party	Value of transaction	uic au	isaction	davan	es or investment					
P.	AN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	transaction as approved by the audit committee	during the reporting period	Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)		1	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest	Tenure	Secured, unsecure

Si No	r o. Name	PAN	Name F	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	Value of the related party transaction as approved by the audit committee		Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost Tenu	- 1	Nature (loan/ advance/ ntercorporate deposit/ investment)	Interest	Tenure	Purpose for which the funds will be utilised by ultimate recipient of fu (endusage)
20	04 Lupin Atlantis Holdings SA, Switzerland		Lupin Pharmaceuticals Inc. USA		Fellow Subsidiary	Payables		0.00	476.16	0.84								

No	o. Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	the audit committee	period	Opening balance	 Nature of indebtedness (loan/ issuance of debt/ any other etc.)	 Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	I Interest I		Purpose for which the funds will be utilised by th ultimate recipient of fund (endusage)

PAN

entering into the transaction

Name

243 Lupin Atlantis Holdings SA, Switzerland

244 Lupin Atlantis Holdings SA, Switzerland

245 Lupin Atlantis Holdings SA, Switzerland

246 Lupin Atlantis Holdings SA, Switzerland

247 Lupin Atlantis Holdings SA, Switzerland

248 Lupin Atlantis Holdings SA, Switzerland

249 Lupin Atlantis Holdings SA, Switzerland

250 Lupin Atlantis Holdings SA, Switzerland

251 Nanomi B.V., Netherlands

252 Nanomi B.V., Netherlands

253 Nanomi B.V., Netherlands

254 Nanomi B.V., Netherlands

255 Nanomi B.V., Netherlands

256 Nanomi B.V., Netherlands

257 Nanomi B.V., Netherlands

258 Nanomi B.V., Netherlands

259 Nanomi B.V., Netherlands

260 Nanomi B.V., Netherlands

261 Nanomi B.V., Netherlands

262 Nanomi B.V., Netherlands

263 Nanomi B.V., Netherlands

270 Lupin Inc., USA

271 Lupin Inc., USA

272 Lupin Inc., USA

273 Lupin Inc., USA

274 Lupin Inc., USA

275 Lupin Inc., USA

276 Lupin Inc., USA

277 Lupin Oncology Inc., USA

278 Lupin Oncology Inc., USA

279 Lupin Management Inc., USA

280 Lupin Management Inc., USA

281 Lupin Management Inc., USA

282 Lupin Management Inc., USA

283 Lupin Management Inc., USA

284 Lupin Management Inc., USA

285 Lupin Management Inc., USA

286 Lupin Management Inc., USA

287 Lupin Management Inc., USA

288 Lupin Management Inc., USA

289 Lupin Management Inc., USA

290 Lupin Management Inc., USA

291 Lupin Management Inc., USA

292 Lupin Management Inc., USA

293 Lupin Management Inc., USA

294 Lupin Management Inc., USA

264 Hormosan Pharma GmbH, Germany

265 Hormosan Pharma GmbH, Germany

266 Hormosan Pharma GmbH, Germany

267 Hormosan Pharma GmbH, Germany

268 Hormosan Pharma GmbH, Germany

269 Hormosan Pharma GmbH, Germany

Details of the party (listed entity /subsidiary)

Name

upin Europe GmbH, Germany

ormosan Pharma GmbH, Germany

upin Pharma Canada Limited Canada

upin Pharma Canada Limited Canada

upin Pharma Canada Limited Canada

Medquimica Industria Farmaceutica LTDA Brazi

Medquimica Industria Farmaceutica LTDA Brazil

Pharma Dynamics (Proprietary) Limited, South

Medquimica Industria Farmaceutica LTDA Braz

Multicare Pharmaceuticals Philippines Inc.

Multicare Pharmaceuticals Philippines Inc.

Generic Health Pty Limited, Australia

Hormosan Pharma GmbH, Germany

Hormosan Pharma GmbH, Germany

Lupin Mexico S.A. de C.V., Mexico

Generic Health SDN. BHD., Malaysia

Lupin Philippines Inc. Philippines

Lupin Europe GmbH, Germany

Lupin Europe GmbH, Germany

Lupin Europe GmbH, Germany

Lupin Europe GmbH, Germany

Nanomi B.V., Netherlands

Nanomi B.V., Netherlands

Lupin Oncology Inc., USA

upin Oncology Inc., USA

Lupin Research Inc. USA

Lupin Research Inc. USA

Lupin Management Inc., USA

Nanomi B.V., Netherlands

Lupin Oncology Inc., USA

upin Oncology Inc., USA

Lupin Inc., USA

Philippines

Lupin Pharma Canada Limited Canada

Lupin Pharma Canada Limited Canada

Lupin Pharma Canada Limited Canada

Medguimica Industria Farmaceutica LTDA Brazil

Multicare Pharmaceuticals Philippines Inc.

Laboratorios Grin S.A. de C.V., Mexico

Generic Health Pty Limited, Australia

Lupin Pharma Canada Limited Canada

Lupin Pharma Canada Limited Canada

Generic Health Ptv Limited, Australia

Generic Health Ptv Limited, Australia

Laboratorios Grin S.A. de C.V., Mexico

Laboratorios Grin S.A. de C.V., Mexico

Lupin Pharma Canada Limited Canada

upin Pharma Canada Limited Canada

Medquimica Industria Farmaceutica LTDA Brazil

upin Research Inc. USA

L Biologics Ltd., Japan

L Biologics Ltd., Japan

Philippines

Philippines

Lupin Inc., USA

Details of the counterparty

PAN

Relationship of the

counterparty with the listed

entity or its subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

lointly Controlled Entity

Jointly Controlled Entity

Fellow Subsidiary

ellow Subsidiary

Fellow Subsidiary

ellow Subsidiary

Fellow Subsidiary

Rs. in Million

Purpose for which the

funds will be utilised by th

ultimate recipient of funds

(endusage)

Details of the loans, inter-corporate deposits, advances or investments

Tenure

4.00% 3 yrs

Unsecured Business Purpose

0.75% 2 yrs Unsecured Business Purpose

Secured/

nterest

Rate (%)

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Nature (loan/ advance/

investment)

Cost | Tenure | intercorporate deposit/

Loan

In case monies are due to

ither party as a result o

the transaction

Closing

balance

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

n nr

1188.67

1207.73

6878.78

250.56

52.15

59 89

9.29

60232.04

1316.7

126.33

0.00

0.00

0.00

0.28

7.23

0.00

n nr

0.00

0.00

14.33

2.74

10.08

9.96

9.98

2.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

909.50

14.33

0.0

650.76

Opening

balance

0.00

0.00

0.00

0.00

0.00

20.40

606.34

0.00

0.00

1188.67

1207.73

6878.78

250.56

52.15

59 89

9.29

60232.04

1316.7

126.33

0.00

0.00

0.00

0.00

0.08

1.13

0.07

0.00

158.50

909 50

0.00

0.00

24.34

13.43

3.95

10.68

0.00

0.00

0.00

0.00

0.00

0.00

0.00

Value of transaction

during the reporting

period

16.76

2 20

0.00

0.43

0.00

0.00

4.24

44.42

12.75

125 66

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

4.71

17.93

0.39

0.00

0.26

0.00

0.00

0.00

21 95

0.00

0.00

10.66

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

3.64

0.5

18.83

6.54

0.3

4.35

0.63

Value of the related party

transaction as approved by

the audit committee

Type of related party transaction

Expenses incurred on our behalf reimbursed & Other

Reimbursements

Reimbursements

Reimbursements

Reimbursements

Reimbursements

Reimbursements

Reimbursements

Interest received

Dividend received

Investment

Investment

Investment

Investment

Investment

Investment

Investment

Investment

Investment

Purchase of goods or services

Legal and Professional Expenses

Expenses incurred on their behal-

Sale of goods or services

Sale of goods or services

Interest received

Receivables

Receivables

Receivables

recovered

Receivables

Loan

Payables

Payables

Receivables

Receivables

Receivables

Receivables

Receivables

Receivables

recovered

recovered

recovered

recovered

Sale of goods or services

Expenses incurred on their behalf

Expenses incurred on their behalf

Expenses incurred on their behal

Expenses incurred on their behalf

Payables

Pavables

Loan

Payables

Receivables

In case any financial indebtedness is incurred to

make or give loans, inter-corporate deposits.

advances or investments

indebtedness

debtedness (loan/ Details of other

Nature of

issuance of debt/

any other etc.)

Details of the party (listed entity /subsidiary) Details of the counterparty entering into the transaction Value of the related party Value of transaction transaction as approved by Type of related party transaction Relationship of the the audit committee PAN Name PAN | counterparty with the listed Name entity or its subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidian

Fellow Subsidiary

ellow Subsidiary

Fellow Subsidiary

ellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

Fellow Subsidiary

ellow Subsidiary

Fellow Subsidiary

ellow Subsidiary

Fellow Subsidiary

Medquimica Industria Farmaceutica LTDA Brazi

Multicare Pharmaceuticals Philippines Inc.

Multicare Pharmaceuticals Philippines Inc.

Lupin Pharma Canada Limited Canada

Lupin Pharma Canada Limited Canada

Lupin Pharma Canada Limited Canada

Philippines

Philippines

Nanomi B.V., Netherlands

lanomi B.V., Netherlands

Lupin Research Inc. USA

Nanomi B.V., Netherlands

Nanomi B.V., Netherlands

Lupin Management Inc., USA

Lupin Pharmaceuticals Inc. USA

Lupin Pharmaceuticals Inc. USA

Lupin Pharmaceuticals Inc. USA

Lupin Research Inc. USA

Lupin Research Inc. USA

Lupin Research Inc. USA

Novel Laboratories Inc. USA

Novel Laboratories Inc. USA

Lupin Management Inc., USA

Lupin Pharmaceuticals Inc. USA

Lupin Pharmaceuticals Inc. USA

upin Pharmaceuticals Inc. USA

Lupin Management Inc., USA

Novel Laboratories Inc. USA

Lupin Research Inc. USA

upin Research Inc. USA

upin Management Inc., USA

Novel Laboratories Inc. USA

upin Pharmaceuticals Inc. USA

Lupin Pharmaceuticals Inc. USA

Lupin Management Inc., USA

Lupin Management Inc., USA

Lupin Management Inc., USA

Lupin Pharmaceuticals Inc. USA

upin Inc., USA

Lupin Inc., USA

Lupin Inc., USA

Lupin Inc., USA

Lupin Inc., USA

Lunin Inc., USA

upin Inc., USA

Lupin Inc., USA

Lupin Inc., USA

upin Inc., USA

Lupin Inc., USA

Lupin Inc., USA

Lupin Research Inc. USA

Lupin Management Inc., USA

Novel Laboratories Inc. USA

Lupin Research Inc. USA

Lupin Research Inc. USA

Novel Laboratories Inc. USA

Novel Laboratories Inc. USA

Lupin Management Inc., USA

upin Management Inc., USA

Lupin Pharmaceuticals Inc. USA

Lupin Pharmaceuticals Inc. USA

Lupin Research Inc. USA

Lupin Management Inc., USA

Novel Laboratories Inc. USA

Lupin Management Inc., USA

Lupin Pharmaceuticals Inc. USA

Lupin Inc., USA

Details of Related Parties transactions during the period April 1, 2022 to September 30, 2022

295 Lupin Management Inc., USA

296 Lupin Management Inc., USA

297 Lupin Management Inc., USA

298 Lupin Management Inc., USA

299 Lupin Management Inc., USA

300 Lupin Pharmaceuticals Inc. USA

301 Lupin Pharmaceuticals Inc. USA

302 Lupin Pharmaceuticals Inc. USA

303 Lupin Pharmaceuticals Inc. USA

306 Lupin Pharma Canada Limited Canada

307 Lupin Pharma Canada Limited Canada

308 Lupin Pharma Canada Limited Canada

304 Lupin Research Inc. USA

305 Lupin Research Inc. USA

309 Lupin Inc., USA

310 Lupin Inc., USA

311 Lupin Inc., USA

312 Lupin Inc., USA

313 Lupin Inc., USA

314 Lupin Inc., USA

315 Lupin Inc., USA

316 Lupin Inc., USA

317 Lupin Inc., USA

318 Lupin Inc., USA

319 Lupin Inc., USA

320 Lupin Inc., USA

321 Lupin Inc., USA

322 Lupin Inc., USA

323 Lupin Inc., USA

324 Lupin Inc., USA

325 Lupin Inc., USA

326 Lupin Inc., USA

327 Lupin Inc., USA

328 Lupin Inc., USA

329 Novel Laboratories Inc. USA

330 Novel Laboratories Inc. USA

331 Novel Laboratories Inc. USA

332 Novel Laboratories Inc. USA

333 Novel Laboratories Inc. USA

334 Novel Laboratories Inc. USA

335 Novel Laboratories Inc. USA

336 Lupin Research Inc. USA

337 Lupin Research Inc. USA

338 Lupin Research Inc. USA

339 Lupin Research Inc. USA

340 Lupin Research Inc. USA

341 Lupin Research Inc. USA

342 Lupin Pharmaceuticals Inc. USA

343 Lupin Pharmaceuticals Inc. USA

344 Lupin Pharmaceuticals Inc. USA

345 Lupin Pharmaceuticals Inc. USA

346 Lupin Pharmaceuticals Inc. USA

347 Lupin Pharmaceuticals Inc. USA

348 Lupin Pharmaceuticals Inc. USA

349 Lupin Pharmaceuticals Inc. USA

350 Lupin Pharmaceuticals Inc. USA

351 Lupin Pharmaceuticals Inc. USA

352 Lupin Pharmaceuticals Inc. USA

353 Lupin Pharmaceuticals Inc. USA

354 Lupin Pharmaceuticals Inc. USA

355 Lupin Pharmaceuticals Inc. USA

356 Lupin Pharmaceuticals Inc. USA

357 Lupin Management Inc., USA

358 Lupin Management Inc., USA

359 Lupin Management Inc., USA

Expenses incurred on their behalf

Expenses incurred on their behal-

Expenses incurred on their behal

Expenses incurred on their beha

Expenses incurred on their behal-

Sale of goods or services

recovered

recovered

recovered

recovered

Receivables

Receivables

Receivables

recovered

Payables

Payables

Investment

Receivables

Receivables

Investment

Receivables

Receivables

Payables

Payables

Payables

Payables

recovered

recovered

recovered

recovered

recovered

Receivables

recovered

Receivables

Payables

Payables

Payables

Payables

Receivables

recovered

Receivables

Receivables

Receivables

recovered

recovered

recovered

recovered

recovered

Payables

Pavables

Investment

Sale of goods or services

Sale of goods or services Expenses incurred on their behal

Expenses incurred on their behal-

Expenses incurred on their behalf

Expenses incurred on their behalf

Expenses incurred on their behalf

Expenses incurred on their behal

Sale of goods or services

Sale of goods or services

Sale of goods or services Expenses incurred on their hehal-

Sale of goods or services Expenses incurred on their hehal

Sale of goods or services

Sale of goods or services Expenses incurred on their behal

Sale of goods or services

Expenses incurred on their behalf

Expenses incurred on their behal

Expenses incurred on their beha

during the reporting period 2.48

16.31

2.2

8.98

0.64

1.35

2.09

0.00

0.00

26.56

0.00

0.08

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

6532.29

70.20

31.45

36.29

35.16

13.03

20.28

18 10

14.22

30.98

0.00

24.09

2892.29

222.62

0.00

0.00

0.00

0.00

0.00

0.00

517.13

193.36

0.00

0.00

0.00

0.00

0.00

4.87

12.9

8 16

37.10

39.04

6.01

58.26

7.34

15.29

18.56

5.93

n case monies are due to

ither party as a result o

the transaction

Closing

0.00

0.00

0.00

0.00

n nr

0.00

0.00

0.00

1.30

0.00

2.42

1.30

0.00

610.42

153.89

769.13

0.00

13.83

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.62

0.00

0.00

11.82 4.23

153.89

2.65

0.00

0.00

0.00

4 23

0.00

0.62

5.09

0.00

0.00

0.00

0.00

0.0

0.00

0.00

0.00

0.00

0.00

0.00

0.00

20809.87

1414.60

0809.87

1414.60

6172.57

27.56

Opening

balance

0.00

0.00

0.00

0.00

0.00

0.00

0.00

4.70

0.97

0.00

39.86

1.07

0.96

610.42

0.00

0.00

769.10

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

1235.70

6172.57

11072.40

In case any financial indebtedness is incurred to

make or give loans, inter-corporate deposits,

advances or investments

indebtedness

debtedness (loan/ Details of other

Nature of

issuance of debt/

any other etc.)

Rs. in Million

Purpose for which the

funds will be utilised by the

ultimate recipient of fund:

(endusage)

Details of the loans, inter-corporate deposits, advances or investments

Tenure

Secured/

nterest

Rate (%)

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Nature (loan/ advance/

investment)

Cost | Tenure | intercorporate deposit/

Det	ails of Related Parties transactions during the	perio	d April 1, 2022 to September 30, 2022																Rs. in Million
													nade o	r given b		ry. These d	etails ne		s to loans, inter-corporate osed only once, during the
c.	Details of the party (listed entity /subsidian entering into the transaction	ary)	Details of the cour	nterpar	ty		Value of the related party		either party	ies are due to as a result of nsaction	In case any financia make or give loar advanc		e depo		Details of the loa	ns, inter-cor	porate d	eposits, adva	nces or investments
No.	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	transaction as approved by the audit committee	during the reporting period	Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
366	Lupin Management Inc., USA		Lupin Research Inc. USA		Fellow Subsidiary	Expenses incurred on their behalf recovered		0.70	0.00	0.00									
	Lupin Management Inc., USA		Novel Laboratories Inc. USA	-	,	Sale of goods or services		18.76	0.00	0.00			\rightarrow						
301	Lapin Wanagement Inc., OSA		Novel Eaboratories Inc. OSA		Tellow Subsidiary	Expenses incurred on their behalf		10.70	0.00	0.00			_						
362	Lupin Management Inc., USA		Novel Laboratories Inc. USA		Fellow Subsidiary	recovered		3.14	0.00	0.00									
	Lupin Management Inc., USA		Lupin Inc., USA		Fellow Subsidiary	Sale of goods or services		79.31	0.00	0.00									
			•		,	Expenses incurred on their behalf													
364	Lupin Management Inc., USA		Lupin Inc., USA		Fellow Subsidiary	recovered		9.07	0.00										
365	Lupin Management Inc., USA		Lupin Research Inc. USA		Fellow Subsidiary	Receivables		0.00	0.00	2.65									
366	Lupin Management Inc., USA		Novel Laboratories Inc. USA			Receivables		0.00	16.57	11.82									
	Lupin Management Inc., USA		Lupin Inc., USA	-		Receivables		0.00	5.14	0.00									
	Lupin Management Inc., USA		Lupin Pharmaceuticals Inc. USA	_		Payables		0.00	2.20										
	Lupin Management Inc., USA		Lupin Research Inc. USA	_		Payables		0.00	3.94	0.00									
	Lupin Management Inc., USA	_	Lupin Inc., USA	1	Fellow Subsidiary	Payables		0.00	0.00	13.83									
	Southern Cross Pharma Pty Limited Australia		Generic Health Pty Limited, Australia		Fellow Subsidiary	Sale of goods or services		12.19	0.00	0.00									